The QualityStocks Daily Monday, July 26th, 2021

Today's Top 3 Investment Newsletters

Tip.us(VMHG) $0.1820 +119.28%

BUYINS.NET(BTBT) $8.8700 +109.69%

QualityStocks(FLGC) $4.5200 +49.67%

The QualityStocks Daily Stock List

Intrusion (INTZ)

QualityStocks, MarketBeat, Marketbeat.com, TradersPro, PennyOmega, OTC Picks and OTC Markets Group reported earlier on Intrusion (INTZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Intrusion Inc. (NASDAQ: INTZ) is engaged in the provision of network security solutions and services.

The firm has its headquarters in Richardson, Texas and was incorporated in September 1983 by G. Ward Paxton and T. Joe Head. Prior to its name change in November 2001, the firm was known as Intrusion.com Inc. It operates as part of the software and tech services industry, under the technology sector, in the software sub-industry.

The company specializes in the development and marketing of advanced persistent threat detection, cybercrime, data mining and entity identification products. It serves firms ranging from mid-market to large enterprises, local and state government entities and U.S. federal government entities, via value-added resellers and its direct sales force.

The enterprise’s products include a network monitoring solution known as INTRUSION Savant which identifies suspicious traffic; a data tool which holds an inventory of network enrichments and selectors to support forensic investigations known as INTRUSION TraceCop; and a network detection and response security-as-a-service solution that identifies and stops attacks and ransomware dubbed INTRUSION Shield. In addition to this, the enterprise provides post-and pre-sales support services like system installation and technical consulting services, and is involved in the resale of commercially available servers and computers from different vendors.

The global recognition and interest in the firm’s Shield solution has been growing, with the firm recently revealing that is now focused on entering into constructive long-term strategic agreements which will allow the company to achieve its operating objectives, maximize shareholder value and help it grow.

Intrusion (INTZ), closed Monday’s trading session at $3.38, off by 12.6615%, on 494,993 volume. The average volume for the last 3 months is 395,675 and the stock's 52-week low/high is $3.32999992/$29.8999996.

Aprea Therapeutics (APRE)

MarketClub Analysis, PennyStocks24, MyBestStockAlerts, Actual Gains, MarketBeat, The Stock Psycho, Stock Roach, Top Gun, Mina Mar Marketing Group, InvestorSoup, Penny Picks, Penny Stock Newsletter, Penny Stocks Finder, PennyPickAlerts, Hot Stock Profits, Trades Of The Day, Honest Abe, OtcShortReport, Greenbackers, Fortune Stock Alerts, Fast Moving Stocks, Damn Good Penny Picks, Stock Preacher, BUYINS.NET, Beacon Equity Research, PennyStockRumors.net, FeedBlitz, HotStockProfits, Club Penny Stocks Network, Center Stage Stocks, Market Wrap Daily, MarketWireStocks, MicroStockProfit, OTC Stock Review, PennyStockProfessor, Pennystocktweeters.com, PREPUMP STOCKS, QualityStocks, Real Pennies, RockingPennyStocks, Stock Legends, StockHideout, Stocktamer, TooNiceStocks, TopPennyStockMovers and Orbit Stocks reported earlier on Aprea Therapeutics (APRE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aprea Therapeutics Inc. (NASDAQ: APRE) is a biopharmaceutical firm that is focused on the development and commercialization of cancer therapies that reactivate the mutant p53 tumor suppressor protein.

The firm has its headquarters in Boston, Massachusetts and was incorporated in 2006. It operates as part of the healthcare sector, in the biotech and pharma sub-industry and serves consumers in Sweden and the U.S.

The company’s primary shareholders include KCIF Co-Investment Fund KB, Rosetta Capital Ltd. and an investment vehicle owned by Karolinska Development AB called KDev Investments AB.

The enterprise’s p53 tumor suppressor protein responds to different forms of cellular stress and activates the transcription of genes which cause apoptosis or cell cycle arrest. Its product portfolio comprises of a p53 reactivator dubbed APR-548, which is undergoing a phase 1 dose-escalation trial for oral administration in patients suffering from myelodysplastic syndromes; and a p53 small molecule reactivator dubbed Eprenetapopt (APR-246), which is currently in late-stage clinical development for various hematologic malignancies as well as other indications. They include acute myeloid leukemia and myelodysplastic syndromes, as well as refractory/relapsed TP53 mutant chronic lymphoid leukemia, non-small cell lung cancer, bladder cancer and gastric cancer. In addition to this, the enterprise is also involved in the development of APR-017, which causes p53-mediated apoptosis by restoring p53 activity in mutant p53 cancer cell lines.

The company recently announced positive results from its trial which evaluated eprenetapopt with azacitidine in the treatment of patients with TP53 mutant acute myeloid leukemia and myelodysplastic syndromes. The success of this new treatment will not only improve patient outcomes for these diseases, which currently have limited treatment options, but also boost investments into the firm, which will have a positive impact on the company’s growth.

Aprea Therapeutics (APRE), closed Monday’s trading session at $4.23, off by 3.2037%, on 1,278,128 volume. The average volume for the last 3 months is 3.48M and the stock's 52-week low/high is $3.88000011/$31.4500007.

Ardelyx (ARDX)

MarketBeat, MarketClub Analysis, InvestorPlace, StockMarketWatch, Investors Alley, TradersPro, Marketbeat.com, Zacks, TopPennyStockMovers, Schaeffer's, Barchart, QualityStocks, The Street, TraderPower, PoliticsAndMyPortfolio, Street Insider, StreetInsider, Top Pros' Top Picks, Jason Bond, TradersPro Morning, Trades Of The Day, INO.com Market Report, Dynamic Wealth Report, Daily Trade Alert and BUYINS.NET reported earlier on Ardelyx (ARDX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ardelyx Inc. (NASDAQ: ARDX) (FRA: 41X) is a biopharmaceutical firm that is engaged in the development and sale of medications for treating cardirenal and kidney ailments.

The firm has its headquarters in Fremont, California and was incorporated in 2007, on October 17th by Jean M. Frechet, Peter G. Schultz and Domonique Charmot. Prior to its name change in June 2008, the firm was known as Nteryx Inc. It operates as part of the healthcare sector, in the biotech and pharma sub-industry and serves consumers across the globe.

The company develops molecules that target receptors and transporters and modulate nutrient uptake or cause the secretion of key hormones, in order to produce a therapeutic benefit in patients. Unlike these systemic products, non-systemic products act from inside the intestines, in order to avoid possible side effects that occur with systemic exposure.

The enterprise’s pipeline comprises of a small molecule program known as RDX020, developed to treat metabolic acidosis; and a small potassium secretagogue molecule program dubbed RDX013, which is currently undergoing a phase 2 clinical trial assessing its effectiveness in treating hyperkalemia. In addition to this, the enterprise also develops a formulation known as tenapanor, which is undergoing a phase 3 clinical trial testing its effectiveness in treating hyperphosphatemia in patients with end-stage renal disease who are on dialysis. The formulation recently concluded phase 3 clinical trials evaluating its efficacy in treating irritable bowel syndrome in patients with constipation.

The company may soon receive approval from the FDA for an NDA application for it tenapanor formulation after it resolves the deficiencies observed in its review. The formulation’s success will not only boost the company’s growth but also encourage investments into the firm.

Ardelyx (ARDX), closed Monday’s trading session at $1.52, off by 9.5238%, on 20,383,591 volume. The average volume for the last 3 months is 5.855M and the stock's 52-week low/high is $1.66999995/$9.22999954.

BioHiTech Global (BHTG)

QualityStocks, NasdaqReport, StockMarketWatch, MarketBeat, StockRockandRoll, Small Cap Firm, PennyStockLocks, Penny Stock 101, AwesomeStocks, StreetInsider, Wall Street Mover, TopNasdaqStocks, Schaeffer's, PoliticsAndMyPortfolio and Marketbeat.com reported earlier on BioHiTech Global (BHTG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BioHiTech Global Inc. (NASDAQ: BHTG) (FRA: 46Q) is engaged in the provision of mechanical, biological and technological engineering solutions of municipal and organic waste around the world.

The firm is based in Chestnut Ridge, New York and was incorporated in 2013 on March 20th. It operates as part of the industrial services industry, under the industrials sector, in the commercial support services sub-industry and serves consumers across the globe.

The company’s primary customers are producers of food waste. It serves stadiums, academic institutions, municipalities, restaurants, hotels, convention centers and food distributors; as well as the hospitality, education, retail food service, prison, grocery and healthcare sectors.

The enterprise’s services and products include traditional disposal services, data analytics tools and food waste digesters. It markets the High Efficiency Biological Treatment Resource Recovery Technology, which processes waste at the enterprise or municipal level, and an aerobic digestion technology solution known as the Revolution Series Digester, which disposes good waste at the point of generation. The enterprise also provides a food disposal and digestion unit that turns waste into grey water which is transported to wastewater treatment facilities via municipal sewer systems, technologies which turn food waste into renewable fuel and real-time data analytics tools that decrease food waste generation. This is in addition to providing the Cirrus and BioHiTech Cloud mobile apps for digester customers.

The firm recently received orders amounting to roughly $2.3 million for its Revolution Series Digesters, which is a testimony to the high value solutions the firm provides. This move will increase its revenues and extend the firm’s consumer reach, which will be good for its growth.

BioHiTech Global (BHTG), closed Monday’s trading session at $1.38, off by 0.719424%, on 211,153 volume. The average volume for the last 3 months is 559,135 and the stock's 52-week low/high is $1.10000002/$4.0300002.

Erytech Pharma S.A. (ERYP)

MarketBeat, StockMarketWatch, StreetInsider and Schaeffer's reported earlier on Erytech Pharma S.A. (ERYP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Erytech Pharma S.A. (NASDAQ: ERYP) (FRA: 2E4) is a biopharmaceutical firm that is focused on the research and development of innovative therapies for orphan ailments and cancer, which are red blood cell-based.

The firm has its headquarters in Lyon, France and was incorporated in 2004, on November 22nd by Yann Godfron and Pierre-Olivier Goineaur. It operates as part of the health care sector, in the biotech and pharma sub-industry and serves consumers in the U.S. and France.

The company is party to a research and collaboration agreement with Queen’s University of Canada, which entails the advancement of the preclinical development of eryminase, developed to treat arginase-1 deficiency; and the Fox Chase Cancer Center, entailing the advancement of the preclinical development of erymethionase, developed to treat homocystinuria.

The enterprise’s product pipeline is made up of a preclinical formulation known as erymethionase, which contains methionine-lyase and has been developed to target cancers dependent on methionine. It also develops eryaspase, which is undergoing a phase 2 clinical trial evaluating its effectiveness in treating hypersensitive acute lymphoblastic leukemia patients and triple-negative breast cancer; and a phase 3 clinical trial assessing its efficacy in treating second-line pancreatic cancer.

The company is planning to submit a Biologics License Application for its eryaspace formulation, developed to treat hypersensitive acute lymphoblastic leukemia. The advancement of this formulation brings it closer to being used as an alternative treatment for patients with this type of leukemia, which would greatly benefit these patients while also bringing in more investors into the firm, which would be good for the company’s growth.

Erytech Pharma S.A. (ERYP), closed Monday’s trading session at $4.5, off by 5.2632%, on 15,822 volume. The average volume for the last 3 months is 13,320 and the stock's 52-week low/high is $4.20450019/$13.9499998.

CarSmartt (CRSM)

QualityStocks and Small Cap Firm reported earlier on CarSmartt (CRSM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CarSmartt Inc. (OTC: CRSM) is a development stage mobility firm that is engaged in the provision of software solutions and services to both travelers and drivers.

The firm has its headquarters in Palo Alto, California and was incorporated in 2007, on February 27th. Prior to its name change in February 2018, the firm was known as Sports Supplement Group Inc. It operates in the technology industry, under the software industry and serves consumers in Italy as well as the United States. The firm is a subsidiary of the Joker Group Inc.

The company’s objective is to make short and long distance travel more affordable and safer. It develops and designs a carpooling application for PC’s and smartphones that provide car rides and seats to carry parcels and transport people. Drivers who use the application retain 90% of earnings from all rides. Additionally, drivers who use the application are subjected to background checks to reassure passengers of their safety.

The carpooling application, dubbed Carsmartt, helps connect drivers with individuals who are travelling long distances and allows long distance sharing. The application offers message alerts, which feature schedules of movement, optimal matches and leads of vehicles. This is in addition to also offering package delivery services in the U.S.

As of September 2020, the firm had entered into an agreement to acquire Nitrotel Manufacturing Corp, which is a leading industry manufacturer of High Quality Network Physical Infrastructure Solutions. This move will facilitate the company’s expansion into new markets, which will increase the firm’s revenue and boost growth as well as attract investments into the firm.

CarSmartt (CRSM), closed Monday’s trading session at $0.05, up 75.4386%, on 25,787,185 volume. The average volume for the last 3 months is 3.975M and the stock's 52-week low/high is $0.0051/$0.054999999.

FEC Resources, Inc. (FECOF)

QualityStocks, Pennybuster and MarketBeat reported earlier on FEC Resources, Inc. (FECOF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FEC Resources, Inc. engages in the acquisition, exploration, and, when warranted, development of natural resource and mineral properties. The Company is a subsidiary of PXP Energy Corporation (Philex) who holds 54.99 percent of the undiluted issued and outstanding capital of FEC. The chief investment of FEC Resources is a 6.80 percent stake in the United Kingdom (UK) company Forum Energy Limited (FEL). The Company previously went by the name Forum Energy Corporation. It changed its name to FEC Resources, Inc. in May of 2005. Incorporated in 1982, FEC Resources is based in Vancouver, British, Columbia. FEC lists on the OTC Markets.

Forum Energy Limited's primary asset is a 70 percent interest in the GSEC101 offshore licence situated to the northwest of the Philippine island of Palawan. This area is roughly 10,360 Km2. It contains the Sampaguita gas discovery, which has expected gas in place of 3.4TCF and potential upside to 20 TCF (Trillion Cubic Feet). Furthermore, FEC Resources has an investment in a gold exploration project in the Philippines.

In addition, the Company owns 8.46 percent, 12.40 percent, and 19.46 percent interests in the SC 14A Nido, SC 14B Matinloc, and SC 14B-1 North Matinloc located in the offshore northwest Palawan. FEC also owns 9.10 percent in SC14C-2; 5.56 percent and 8.18 percent in SC 6A Octon and SC 6B Bonita positioned in the offshore northwest Palawan.

Moreover, FEC Resources owns a 100 percent interest in the SC 40 North Cebu, covering an area of 340,000 hectares in the northern part of Cebu Island and adjacent offshore areas located in the Visayan Basin in the central part of the Philippine Archipelago, and as well as 2.27 percent interest in SC14C-1 Galoc.

FEC Resources previously regrettably announced that Mr. Lyle Brown will be retiring from the Board of the Company for health reasons effective October 31, 2020. At present, Mr. Brown acts as an Independent Non-Executive Director and Chairman of FEC Resources’ Audit Committee.

Mr. Paul Wallace, President of FEC Resources, stated, "We were fortunate indeed to have Lyle join us in 2013. He offered an independent mindset and came with a reputation of being a professional accountant of high integrity. He has provided the Board with his considered and informed views on the various accounting and valuation issues we have faced in recent years. We thank him for his service and wish him the very best for the future."

FEC Resources, Inc. (FECOF), closed Monday’s trading session at $0.0242, up 66.8966%, on 3,116,554 volume. The average volume for the last 3 months is 950,128 and the stock's 52-week low/high is $0.0012/$0.029999999.

Humble Energy, Inc. (HUML)

We reported earlier on Humble Energy, Inc. (HUML), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Humble Energy, Inc. is an oil and gas production and exploration company listed on the OTC Markets. Natural gas is 85 percent of the Company’s production. Humble Energy also owns coal minerals. It owns coal minerals in fee simple title that are high BTU metallurgical quality coal. Additionally, Humble has Coking coal with a high Button nine plus that blends with lesser coals to make steel. Humble Energy has its head office in Paron, Arkansas.

It commenced operations as a private Texas Corporation in 1999 as Humble Petroleum, Inc. In May 2009, Humble Petroleum, Inc. bought Humble Energy, Inc. transferring ownership interests in 83 wells in Texas, Wyoming, New Mexico, Kansas and Oklahoma. The wells purchased 85 percent of the common stock in Humble Energy, Inc. On December 30, 2013, Humble Petroleum, Inc. transferred the remaining assets of Humble Petroleum, Inc. that included oil and natural gas wells, coal, ATTI, and Power Klean. Humble Petroleum, Inc. common shares became Humble Energy, Inc. shares.

Currently, Humble Energy is participating in drilling 10 wells in the prolific Cotton Valley sand formation in Louisiana. The first 9 horizontal wells came in at 108,000,000 cubic feet per day on a 44/64 choke. Because of the successful results of the first 9 wells Humble has agreed to participate in the drilling of 4 more Cotton Valley formation wells.

Furthermore, the Company is participating in the drilling of 7 more wells in the Haynesville shale formation. Twenty more total wells will be drilled. Moreover, Humble has participated in drilling and completing producing horizontal wells in Kingfisher County, Oklahoma. The Company states that production to date has been excellent.

Humble Energy has its Power Klean product. Power Klean cleanses out contaminated motor oil. Tests show that the system removes greater than 85 percent of the harmful contaminates, wear metals, and carbon that typical oil changes miss. Features of Power Clean include lessening friction; extending engine life; increasing horsepower, and improving gas mileage. In addition, features include keeping oil cleaner for higher performance oil changes.

Humble Energy, Inc. (HUML), closed Monday’s trading session at $0.47, up 43.7309%, on 14,403 volume. The average volume for the last 3 months is 28,241 and the stock's 52-week low/high is $0.150999993/$7.9499998.

OBITX, Inc. (OBTX)

RedChip and QualityStocks reported earlier on OBITX, Inc. (OBTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OBITX, Inc. specializes in blockchain technologies and decentralized processing. Its services include Blockchain Development, Blockchain Consulting, as well as Cryptocurrencies. The Company formerly went by the name GigeTech, Inc. It changed its name to OBITX, Inc. in October of 2017. Founded in 2017, the Company is headquartered in Fleming Island, Florida.

The OBITX team consists of business leaders, accountants, and legal advisors that specialize in blockchain technologies. Blockchain Development services include Blockchain based apps and Business Integration with Blockchain. Blockchain Consulting services include Blockchain Processes, Smart Contracts and Tokenomics, and Middle Market Businesses. Cryptocurrencies services include Global Financial Transactions, Interest Bearing Cryptocurrencies, and Entrance to Digital Markets.

OBITX announced in May 2020 that it sold its 420Cloud Social Media Platform to First Bitcoin Capital, Corp., for $1.9 million. The 420Cloud Social Media Platform was transferred to First Bitcoin Capital, Inc., (BITCF) in exchange for $500,000 in First Bitcoin (COIN:BIT) cryptocurrency tokens and a two-year secured convertible promissory note of $1,400,000.

OBITX is embracing Blockchain Technologies and Decentralized Computing. It discontinued its Social Media Marketing business emphasis. The Company is now focusing on its core competency brought by its new management team of blockchain technologies and decentralized computing.

OBITX, Inc. (OBTX), closed Monday’s trading session at $11.45, up 36.3095%, on 70,268 volume. The average volume for the last 3 months is 8,317 and the stock's 52-week low/high is $0.189999997/$19.8999996.

Pura Naturals, Inc. (PNAT)

QualityStocks, Promotion Stock Secrets, Wall Street Mover and PoliticsAndMyPortfolio reported earlier on Pura Naturals, Inc. (PNAT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pura Naturals, Inc. is working to deliver a purer clean by way of its innovative BeBetter Foam®. The Company is the manufacturer of unique foam cleaning products for the home. It has its proprietary foam technology, which absorbs grease and grime like a magnet. It does so without harsh chemicals and harboring of bacteria found within traditional household cleaning products and sponges. Pura Naturals is based in Lake Forest, California.

The Company focuses on plant-based products made from renewable resources with no petroleum by-products. Its product portfolio includes Health & Beauty products, including facial pads, exfoliating soap-infused body bars, soap-infused sponges, and soap-infused gentle cleansing pads for babies.

Kitchen & Household products include sponges, soap-infused sponges, non-scratch scrubbers, and non-scratch scrubbers (soap-infused). Pura Naturals’ household cleaning products deliver a unique soap infusion. The ground-breaking foam absorbs grease while repelling water and inhibiting bacteria growth and odors.  

Pura Naturals also has its Pura Naturals Marine. The specific design of its marine foam is to handle petroleum base contaminations. It is approved for use by the Environmental Protection Agency (EPA). Marine products include all-purpose sorbent Spill Pads, bilge sorbent Bilge Booms, Spill Bibs (fuel spill prevention), soap-infused personal cleaning bars, and soap-infused galley sponges.

The Pura Marine division centers on developing solutions employing AirTech Foam technologies and allied products directed towards oil spill prevention and remediation in waterways. This division is pursuing business in the trucking and oil sectors. Additionally, Pura Naturals has its all-natural cleaning solution, Pura Pro Bio-Degreaser. This product is a strong citrus based, multi-use cleaner.

Pura Naturals, Inc. (PNAT), closed Monday’s trading session at $0.0041, up 51.8519%, on 15,224,124 volume. The average volume for the last 3 months is 1.147M and the stock's 52-week low/high is $0.0012/$0.008999999.

Atacama Resources International, Inc. (ACRL)

QualityStocks, Wolf of Penny Stocks, Epic Stock Picks, ProTrader, PHUB News, Penny Stock Titans, Penny Picks, Monster Alerts, MicroCapDaily, MegaPennyStocks, MarketBeat, DSR News and Damn Good Penny Picks reported earlier on Atacama Resources International, Inc. (ACRL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Atacama Resources International, Inc. has significant mining claims in the greater Kirkland Lake area of Northern Ontario. Metals and minerals under potential exploration include gold, silver, diamonds, graphite and cobalt. Furthermore, major deposits of copper and iron ore are included in the mining claims. Atacama Resources International is headquartered in Plantation, Florida.  

Regarding Minerals, the Company has numerous claims on 4460 acres in the Kirkland Lake and other areas of mineral-rich northern Ontario. The Company’s initial line of business is a combination of mining, acquisition, as well as development of mining interests in the Kirkland Lake region.

Atacama Resources International announced last September that it engaged Canadian Exploration Services Ltd. (CXS) to conduct a geological evaluation of the Company’s Cabo property. The Cabo property comprises Mining Claim 4225513, located in the Township of Lorrain in the heart of all the high-profile cobalt activity surrounding the historic mining town of Cobalt, Ontario.

Atacama Resources has acquired the mineral rights for the Mystery Graphite Property that comprises 1740 acres situated roughly 60 miles south of Timmins, Ontario. The acquisition of the mineral rights includes receiving core samples collected from numerous diamond drill sites earlier conducted on the property.

Additionally, Atacama Resources is involved in a new line of business that it states will make the highways of the U.S. and Canada safer and saves lives in the process. The Company, as part of its expansion portfolio, acquired Good2Drive™, Inc. Good2Drive, Inc. is a wholly-owned subsidiary of Atacama Resources International.   

Good2Drive™ is an entity that has the rights to an application (app), which detects levels of cognitive awareness and reports those levels in accordance with the users' demands and needs. The Company’s technology business includes the innovative Smartphone application Good2Drive and also follow on products that will be released this year.   

Atacama Resources International released Good2Drive in 2017. Good2Drive is a mobile application that enables drivers, corporate fleets, and law enforcement to test a driver's cognitive alertness before getting behind the wheel of a motor vehicle. Good2Drive uses a 60-90 second image matching test using a patented algorithm that was created based on the scientific study of cognitive abilities at different West Coast hospitals and universities. 

Good2Drive’s dedication is to providing Smartphone hosted applications founded on its proprietary testing for cognitive awareness. Its set of Smartphone hosted apps will include cognitive tests for care givers, seniors with impairments, remote employees in potentially hazardous environments, and other situations where it is necessary to be cognitively alert.

Atacama Resources International also has its Good2Drive/Fleet. This is a mobile application. It enables commercial fleet owners and operators to manage manifold drivers as they test their mental alertness before getting behind the wheel of a vehicle.

Atacama Resources International, Inc. (ACRL), closed Monday’s trading session at $0.028, up 44.3299%, on 1,976,414 volume. The average volume for the last 3 months is 1.702M and the stock's 52-week low/high is $0.0043/$0.05.

Appreciated Media Holdings Inc. (AMEFF)

We reported earlier on Appreciated Media Holdings Inc. (AMEFF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Appreciated Media (TSX.V: AMH) (OTCQB: AMEFF) has filed amended and restated interim financial statements as well as an amended and restated corresponding management's discussion and analysis; the filings were for the interim periods ended Sept. 30, 2020, and Dec. 31, 2020. According to the announcement, the amended financial reports include more fulsome disclosure pertaining to the assignment of various receivables and liabilities to third parties in connection with AMEFF’s internal restructuring as well as several corrections.

Those corrections include changing the comparative period for the balance sheet from Dec. 31, 2019, to June 30, 2020, and changing the comparative period for the statement of cash flows to reflect the six months ended Dec. 31, 2019, rather than Dec. 31, 2020. The new filings also amend note 5 to include transactions for the year-to-date period of the six months ended Dec. 31, 2020, as well as updating the subsequent event note to provide a more comprehensive overview of upcoming events and removing language that was both subjective and promotional. Finally, the new filings reconcile cash from operating activities and cash from financing activities in the Dec. 31, 2020, to the corresponding amounts in the statement of cash flows.

To view the full press release, visit https://ibn.fm/X6M5t

Appreciated is a worldwide film and television media production-packaging company whose core business is producing independent films and television movies for global business-to-business distribution. For more information about the company, please visit www.AppreciatedMedia.com.

Appreciated Media Holdings Inc. (AMEFF), closed Monday’s trading session at $0.02, even for the day, on 20,000 volume. The average volume for the last 3 months is 21,924 and the stock's 52-week low/high is $0.000099999/$0.129999995.

The QualityStocks Company Corner

Accure Acne Inc.

The QualityStocks Daily Newsletter would like to spotlight Accure Acne Inc..

Accure Acne Inc. was featured today in a publication detailing various investment considerations and how the company is “One to Watch.”

  • Accure Acne’s groundbreaking Accure Laser System is the first commercially developed energy-based device that selectively targets and neutralizes overactive sebaceous glands
  • The innovative technology is expected to position Accure as a disruptor on the vast global market of acne treatments
  • By targeting only overactive glands, the system offers enhanced efficacy and a durable response; safety and efficacy have been confirmed by four IBR-approved clinical trials
  • An early adopter program is already underway in the European Union, with the first orders received and delivered in Italy in Q2 2021; a broader commercial launch in several European countries is currently slated for H2 2021
  • The company restarted a pivotal acne study in January 2021, with initial results expected in early 2022; this study will be essential for FDA approval in view of beginning U.S. commercialization in 2022
  • Accure Acne boasts highly experienced management and scientific teams, leveraging decades of expertise in the aesthetics and medical device markets
  • The company was co-founded by one of the most influential scientists in the field of energy-based devices and the co-developer of microscopic target-selective laser therapy

Accure Acne Inc. is a privately-owned medical device company focused on developing an innovative and highly efficient solution to reducing and/or preventing the recurrence of acne vulgaris. The company’s patented and patent-pending laser technology was designed to help improve acne sufferers’ long-term quality of life by offering a differentiated and impactful solution.

Leveraging the extensive experience of its management and scientific teams, paired with a clear go-to-market strategy and commercialization and regulatory expertise, Accure remains committed to developing a uniquely compelling value proposition.

Accure Acne is headquartered in Boulder, Colorado. The company’s flagship product, the Accure Laser System, was granted CE Mark approval for the treatment of moderate inflammatory acne in 2020, which allows the company to commercialize its product in the European Union while working to develop an exclusive global IP portfolio.

Accure Laser System

The company’s pioneering technology has the potential to disrupt the vast global market of acne therapeutics. It is estimated that there are 40-50 million people affected by acne vulgaris in the United States each year, while roughly 85 percent of the global population will suffer from acne at some point, according to the company’s April 2021 investor presentation. In 2016, the acne vulgaris market was estimated at $2.6 billion in the U.S. alone.

Accure Acne is leveraging several competitive advantages to position itself as a leading company in the acne treatment market. Compared to the main competitors and other acne treatments in the market, the Accure Laser System is designed for efficacy and durable results, in a cost-effective treatment package.

This groundbreaking system is the first commercially developed energy-based device that selectively targets and neutralizes overactive sebaceous glands present in the skin, which are the main source of sebum production and acne vulgaris. By targeting only overactive glands without damaging the surrounding epidermis, the Acne Laser System is likely to yield a durable response, starting with a significant reduction of inflammatory acne lesions, with the goal of eliminating inflammation recurrence in treated areas. The system has been shown to yield a 45%+ reduction in inflammation after just one treatment.

Other key features of the Accure Laser System include:

  • Utilizes a unique wavelength that has not previously been clinically available
  • Leverages unique pulsing strategy, precise and safe closed-loop laser control and integrated temperature monitoring through an infrared camera
  • Is designed for ease of use and relatively short treatment time (30 to 45 minutes)
  • Is equipped with single-use treatment tip and accessories

Treatments are customized to each patient, depending on skin types and case severity, and can range from one to six treatment sessions administered three to six weeks apart.

Accure Acne believes its technology is the only 1,726 nm laser with CE Mark Clearance for acne treatment on the market. The Accure Laser System was developed in partnership with Quanta System, a Milan, Italy, laser tech developer with over four decades of experience.

The company has already launched an early adopter program in the European Union, with the first orders received and delivered in Italy in Q2 2021, through Quanta’s distribution channel. A broader EU commercial launch is scheduled for H2 2021, with plans for an early adopter program in the U.S. to begin in H1 2022 and broader commercial launch in H2 2022.

New Pivotal Acne Study

The Accure Laser System’s efficiency and safety of treatment across all genders, ages, races and skin types has so far been confirmed through four IRB-approved clinical studies. Research showed a 45% reduction of acne lesions after just one treatment and an 80% reduction after the fourth treatment.

Accure Acne is now conducting a new pivotal acne study, restarted in January 2021, based on safety reports from the four IRB-approved clinical trials. This open-label study will enroll 75 patients 16 years and older who will undergo four treatments approximately one month apart.

The study is expected to be completed in early 2022, following several checkpoints to monitor for progress and durability – at three months, six months, nine months and 12 months after the fourth and final treatment. This clinical trial will be key to the company’s efforts to secure FDA approval in the United States.

Private Placement Offering

Accure Acne launched a private placement offering pursuant to Rule 506(c) of Regulation D under the Securities Act. The private placement, launched in April 2021 on the M-Vest platform, aims to raise up to $20 million in Series A Convertible preferred stock.

The proceeds will be used to fund the pivotal acne study, ongoing operations and infrastructure needs, while also creating an EU-based sales team and global marketing teams and conducting pre-commercialization operations in the U.S.

For more information, visit the company’s offering page on M-Vest.

Management Team

Christopher Carlton is Co-Founder, Chief Executive Officer and Chairman of the Board of Accure Acne. He has extensive industry experience as well as a demonstrated track record of entrepreneurial success with high-growth public companies and new product launches on the global medical and aesthetic markets. His previous tenures include CEO of Quanta Aesthetic Lasers USA LLC; President, NA for Syneron-Candela, a prominent company in the aesthetic energy-based device market; Vice President and Global General Manager – Interventional Oncology for Covidien Ltd.; CEO for SRI Surgical; and other leadership positions. In 2016, he was recognized as one of the top 10 CEOs and presidents in the industry by Aesthetics Everything(R). Mr. Carlton is a graduate of the GE Management Development Institute-Crotonville and the Program on Negotiation at Harvard Law School, and he holds a BS in Industrial Engineering (With Honors), a Graduate Diploma in Management and an MBA.

R. Rox Anderson, MD, is the company’s Co-Founder and Chief Scientific & Medical Officer. One of the most influential scientists in the field of energy-based devices in aesthetics and widely considered the father of the aesthetic industry, Dr. Anderson has contributed significant advancements to acne treatment efforts, including pre-clinical, clinical and product development activities built upon his conceptualization and co-development of microscopic target-selective laser therapy. He has been awarded over 60 national and international patents and has co-authored over 437 scientific books and papers cited by other researchers more than 22,800 times. Dr. Anderson is a Harvard Medical School Professor in dermatology, Director of the Wellman Center for Photomedicine, and adjunct Professor of Health Sciences and Technology at Massachusetts Institute of Technology.

Edward Barbera is Co-Founder and Director of Accure Acne. He has more than 35 years of experience developing, running and investing in startups, as well as fundraising, having secured more than $50 million in private equity for a company he founded. Mr. Barbera began his career as a Senior Consultant with Peat, Marwick, Mitchell & Co. and has since held key leadership roles in business development, acquisitions, capital formation and the operation of numerous startups. He has a Bachelor of Business Administration degree with a major in accounting from the University of Massachusetts – Amherst and has previously been a member of the National and Colorado Societies of CPAs.

The Accure Acne leadership and medical teams are further comprised of experts and professionals with extensive experience in technology, software, engineering and medical devices, as well as specialists in acne treatment and laser-based treatment options in dermatology and other medical fields.


Recent News

chart

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

  • Flora Growth has signed a Letter of Intent with Avaria Inc. to form a joint venture for the sale of its award-winning KaLaya brand across LATAM, including Flora Labs’ 2,500+ Colombian distribution channels.
  • KaLaya has sold over a million units and is currently distributed via major retailers including Loblaws, Walmart, and London drugs across Canada, holding the number one customer retention rate in Loblaws’ pain cream categories.
  • Flora will support the development and production of CBD pain cream formulations for the global market, with an immediate focus on LATAM and import into the United States.

Flora Growth Corp. (NASDAQ: FLGC) (“Flora”, “Flora Growth”, or the “Company”), an all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce it has signed a non-binding Letter of Intent (“LOI”) to form a joint venture (“the JV”) with Canadian based Avaria Inc (“Avaria”), the manufacturer and owner of KaLaya – an award-winning pain cream distributed nation-wide across Canada.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Monday’s trading session at $4.52, up 49.6689%, on 2,130,854 volume. The average volume for the last 3 months is 537,240 and the stock's 52-week low/high is $2.8499999/$6.00.

Recent News

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF)

The QualityStocks Daily Newsletter would like to spotlight Avricore Health Inc. (OTCQB: AVCRF).

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) today announced the signing of the first amendment to its supplier distribution agreement between HealthTab(TM) Inc., a wholly owned subsidiary, and Abbott, a global health care company and diagnostics leader in Canada. According to the update, the agreement, first signed on May 31, 2021, allows HealthTab(TM) to distribute in Canada Abbott’s Afinion(TM) 2, as well as associated tests for diabetes and heart-disease screening in community pharmacies. This includes HbA1c testing, which lead to the subsequent signing of a master agreement with Shoppers Drug Mart to bring this new testing to select locations as an initial pilot program. To view the full press release, visit https://ibn.fm/OTPb4.

  • Avricore Health is an innovator in pharmacy based point-of-care diagnostics
  • The company introduced its flagship technology platform in an Ontario Shoppers Drug Mart pharmacy earlier this month as the lead-out to a 12-store rollout throughout the province
  • Avricore’s trademarked HealthTab network is making diagnostic tools for diabetes and cardiovascular disease management accessible to patients and the Shoppers Drug Mart agreement provides community locations as well as pharmacist support
  • The trial rollout showed successful use by over 90 patients during a week-and-a-half period with seamless pharmacist personnel assistance for more than 600 test results
  • Financing programs in January and February helped Avricore retire $1 million in debt with enough left over to help fund the company’s platform expansion

Pharmacy diagnostics solutions developer Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is celebrating the successful test rollout of its flagship platform for assessing cardiovascular disease and diabetes in Shoppers Drug Mart, Canada’s largest pharmacy network.

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab™ (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

HealthTab

HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets and third-party app integration through API.

Agreement with Shoppers Drug Mart

In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2™ analyzers provided by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near Term Goals

Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies.

Market Outlook

In 2020, the global point-of-care testing (POCT) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (CAGR) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Management Team

Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia.

Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia.

Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Avricore Health Inc. (OTCQB: AVCRF), closed Monday’s trading session at $0.152, up 10.1449%, on 2,900 volume. The average volume for the last 3 months is 8,730 and the stock's 52-week low/high is $0.013269999/$0.485619992.

Recent News

DSG Global Inc. (OTCQB: DSGT)

The QualityStocks Daily Newsletter would like to spotlight DSG Global Inc. (DSGT).

DSG Global (OTCQB: DSGT) today announced the delay of its plan to complete a reverse stock split in connection with a potential listing on a national stock exchange. According to the update, the shareholder approval, as stated in the 14-C, will remain effective until March 2022. DSGT and its board of directors will delay the reverse split and instead seek to strengthen the company’s cash flow and balance sheet. The company is in negotiations to secure available debt (rather than equity) financing to bolster expansion, increase inventory and accelerate sales. To view the full press release, visit https://ibn.fm/0dfpY

DSG Global Inc. (OTCQB: DSGT) is an emerging global technology company with interconnecting businesses in fast growing market sectors. With roots in the golf industry, the company specializes in golf fleet management and is moving quickly into road-ready electric vehicles for delivery in the third quarter of 2021.

In 2019, the company secured exclusive North America distribution rights for Jonway Automobile Co. road-ready electric vehicles (EVs). Jonway, based in Zhejiang, China, began manufacturing new vehicles s in 2003 and today produces Electric powered Cars, Trucks, Vans, SUV’s, and Scooters. Jonway vehicles are exported to more than 80 countries and are built to comply with U.S. safety and environmental standards.

These vehicles are being sold via DSG’s wholly owned subsidiary, Imperium Motor Company (IMC). The move into consumer vehicles capitalizes on the company’s strength in the selection and distribution of EVs, the ability to work with large manufacturers and in application of proprietary technology unique to DSG. DSG’s advanced fleet tracking can be integrated into Jonway EVs to offer a customized scalable and integrated solution to meet the needs of small businesses and large enterprises.

The Future is Electric

With decades of EV experience in golf, including distribution of highly advanced carts, DSG recognized the huge chasm between consumer interest in acquiring road ready EVs versus current EV models’ lack of availability and affordability. As such, the company focused on becoming a distribution and EV brand management company unencumbered by the manufacturing process. The manufacturers take responsibility for building vehicles to DSG’s specifications and fulfillment of regulatory and licensing requirements.

DSG has also established a distribution agreement with Skywell New Energy Automobile Group Ltd., an Asian-based EV manufacturer. Skywell will supply DSG with SUV’s, Passenger Vans, Cargo Vans, Commercial Vehicles and Buses that will be fully certified for use in the United States.

Brands

Imperium Motor Company (IMC) seeks to transform the way the world drives by making greener transportation available to everyone. IMC is an EV sales and marketing company that distributes directly to consumers and through third party distributors, offering a wide variety of affordable vehicles equipped for the North American market. The company’s emphasis is on great design, a green mindset, performance and functionality. Its vehicles include 26 models of high-speed, mid-speed and low-speed electric vehicles including cars, trucks, SUVs, vans, buses and scooters.

Vantage Tag Systems (VTS) is a global leader in the design, manufacture, and marketing of fleet management solutions for the golf industry. VTS has developed the TAG suite of products that represents the industry’s first completely modular fleet management solution. The company’s patented analytics, mobile touch screen GPS units and electric golf carts are sold around the world through a network of established distributors and partnerships with notable brands in fleet and equipment manufacture. VTS solutions also have applications in managing commercial, agricultural, military and government fleets. VTS is a wholly owned subsidiary of DSG Global.

Market Outlook

The global EV market was valued at $273 billion in 2017, according to Fortune Business Insights, and is projected to exceed $987 billion by 2027, with a projected CAGR of 17.4 percent. The relative high manufacturing costs of EVs compared to gasoline-powered vehicles and the resulting higher sticker price to consumers are major obstacles to near term market adoption.

The global e-bike market is estimated to grow to $70 billion by 2027 from its current valuation of $41.1 billion. An estimated 130 million e-bikes are expected to be sold globally over the next two years. The U.S. imported approximately 600,000 e-bikes in 2020, according to the Light Electric Vehicle Association, and its analysts expect that number will grow substantially in 2021.

Management Team

Robert “Bob” Silzer is the CEO of DSG Global. He is a serial entrepreneur who turns technology ideas in high growth industries into profitable businesses. With roots in the golf industry, he founded Vantage Tag Systems in 2008. Vantage Tag Systems is now a DSG subsidiary specializing in GPS-enabled fleet management.

Zahir Loaiza is the interim CFO of DSG Global. She assumed the role in March 2021, after having previously served as the company’s Corporate Controller. Her diverse international experience includes working at a publicly traded mining company, several law firms and more in the U.S., Canada and South America. Prior to pursuing a career in corporate finance, she was the owner of two retail entities.

Rick Curtis is the president and COO of Imperium Motor Company, the automotive subsidiary of DSG Global. His 40-year background in the automotive industry includes manufacturing, vehicle distribution, parts distribution, service management, dealer development and executive management of dealer groups. Prior to joining Imperium, Mr. Curtis served as president of Mullen Technologies and grew the company into a world class provider of electric vehicles, battery technology and energy storage systems.

William “Bill” Rex is president of Imperium Motor’s EV Bus and Motor Home Division. He has more than 40 years’ experience at suppliers of buses/electric buses, motor homes, trucks, specialty vehicles and batteries. He is the founder of Rexhall Industries Inc., formerly a publicly traded manufacturer of RVs and distributor of buses and coaches. He previously served as president of THOR West, a subsidiary of THOR Industries that manufactures shuttle buses, and as president of BYD Coach and Bus.

Patrick J. Parenti is the SVP Global Sales at DSG subsidiary Vantage Tag Systems. He has nearly 30 years of experience in golf and golf course management. Prior to joining DSG in 2012, Mr. Parenti served for 10 years as SVP at ProLink Systems, a leading global provider of GPS golf-course management systems.

Clint Singer is Director of Engineering at Vantage Tag Systems. He has been a senior developer in the golf industry for more than 20 years and has an extensive background in GPS systems.

Daniel Price is Technical Operations Manager of DSG Global’s European Region, UK, South Africa. In addition to his background in mechanical and electronic engineering, he is an audio engineer, specializing in automotive audio and security. He has also worked with high end electronic security companies in the UK and previously owned an electronic security and CCTV company.

Steven Mueller is Operations Manager at Vantage Tag Systems. He worked in the global pulp and paper market for nine years, facilitating the global movement of thousands of tons of timber products annually. Additionally, he has a successful decades-long track record of managing operations and consulting for a wide range of retail businesses.

DSG Global Inc. (DSGT), closed Monday’s trading session at $0.18, up 3.7464%, on 471,140 volume. The average volume for the last 3 months is 841,579 and the stock's 52-week low/high is $0.0108/$1.51999998.

Recent News

Golden Triangle Ventures Inc. (OTC: GTVH)

The QualityStocks Daily Newsletter would like to spotlight Golden Triangle Ventures Inc. (GTVH).

Golden Triangle Ventures (OTC: GTVH) and its subsidiary Lavish Entertainment completed the acquisition of Syndicate Bass Records LLC, a label collection curated by individuals who strongly believe in the impact of the bass music scene around the world. The move enables GTVH to debut its own experimental bass music record label. Commenting on the acquisition, Golden Triangle Ventures vice president Malachi Farrow, who also serves as Syndicate Bass Records CEO, said, “We are excited to follow our passion in the electronic music industry. . . . Everyone on our team has been in the bass music scene searching for the most unique sounds and talents available in the market, and it’s an honor to be a part of something we’ve been so deeply involved in for years.” To view the full article, visit: https://cnw.fm/14lUf

Golden Triangle Ventures Inc. (OTC: GTVH) is a multifaceted consulting company pursuing ventures in the health, entertainment and technology industries, with many additional projects being developed that provide synergistic values to these divisions. The company aims to purchase, acquire and/or joint venture with established entities that management can help assist and develop into unique opportunities.

Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business development objectives. The goods and services represented are driven by innovators who have passion and commitment to these marketplaces.

The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent these three sectors in which the company aims to do business.

Health Division – Global Health Services

Global Health Services is a wholly owned subsidiary of Golden Triangle Ventures (operating under its Health Division). Dedicated to the promotion of well-being and natural wellness, the company currently does business in the industrial hemp/CBD industry. Additionally, the company has a vision to promote, market and generate sales for a myriad of products and services which include a full retail line of high-end, all-natural health, wellness and beauty products.

To help achieve this vision, Global Health Services is in the process of further developing an extensive online portal that will support the multiple verticals under the company and provide a one-stop-shop for all of the company’s products and services. Moreover, to support overarching business goals, senior management tirelessly works on acquiring and building an array of profitable assets and projects.

Entertainment Division – Lavish Entertainment

Lavish Entertainment (EpicRaves) is a wholly owned subsidiary of Golden Triangle Ventures under its Entertainment Division. Operating out of Las Vegas, Nevada, the company started doing business in 2017 and was established with a vision of becoming a nationally recognized concert production company. The company currently has more than 30,000 national followers and nearly 100 team members who have helped the company successfully organize some of the most exciting Electronic Dance Music concerts in Las Vegas.

Lavish Entertainment is currently doing business as EpicRaves, which will eventually become a wholly owned subsidiary of Lavish Entertainment as the company expands its business into a variety of other forms of entertainment. The company is currently building a unique virtual reality platform to help expand on its live events, and it is working to acquire a 68,000 sq. ft. event center with a vision to develop one of the most advanced event centers in the world.

Technology Division – HyFrontier Technology

HyFrontier Technologies is a wholly owned subsidiary of Golden Triangle Ventures under its Technology Division. The company owns a patent-pending process and device technology called HyGrO, which is a molecular hydrogen and oxygen delivery system for agriculture. Golden Triangle Ventures is assisting the company in commercializing the HyGrO unit for farm and home use in markets across the globe. HyFrontier Technologies has a mission to improve global crop production efficiency by producing hydrogen and oxygen directly in the water stream.

This technology can be used on any species of plant life in nearly any grow medium. Additionally, the system can be retrofitted to wellheads for large-scale agricultural projects, indoor grow operations and small farms or utilized for a multitude of residential home and garden applications. In-house testing has shown evidence that hydrogen is capable of increasing crop yields by up to 25% and, in many circumstances, a much higher amount. Larger root systems and better overall plant health were also observed by watering plants with the HyGrO unit. Universities and multiple third-party testing facilities are currently working to validate the HyGrO technology, and all preliminary results are extremely positive.

To push the development and commercialization of the technology, management is now in the process of moving the company headquarters from Colorado to Florida, which will transition its operations into a 7,800 sq. ft. state-of-the-art manufacturing facility. The company recently executed a three-year lease with an option to purchase the entire 24,000 sq. ft. building, which will help the business in achieving its ultimate goal of commercializing this technology to the world.

Food & Wine Division – Napa Wine Brands

Napa Wine Brands is a wholly owned subsidiary of Golden Triangle Ventures which is a synergistic business with a mission of providing a world-class portfolio of unique brands birthed from Napa Valley and Sonoma Valley in the heart of California’s Wine Country.

The company has a commitment to manufacture and distribute specialty wines, foods and unique items while tapping into an array of hidden markets in the food and beverage industry. With extensive resources and award-winning products, Napa Wine Brands aims to develop some of the most desirable products in today’s market. Originated by some of the most profound experts in Napa Valley, the company’s vision is to broaden the horizon of a traditional food and wine company by creating a platform different than anything seen in the Northern Hemisphere.

Napa Wine Brands has an array of fully developed products and services that provide value to the other divisions under Golden Triangle Ventures. The company is now preparing the launch of several brands, products and services that are market-ready and will immediately turn into cash-positive businesses. Golden Triangle Ventures will provide a full support system and assist management of Napa Wine Brands in growing this company into another fun, exciting and profitable division of Golden Triangle Ventures.

Recent Updates

  • On May 26, 2021, Golden Triangle announced its acquisition of The Lodge Winery & Olive Oil Co. under the company’s Napa Wine Brands subsidiary. The Lodge Winery & Olive Oil Co. is an established wine brand that produces award-winning wines, olive oils and wine vinegars. “Our marketing team is now ready to launch an in-depth program focused on driving our products into big box stores, smaller retail outlets, online platforms and many other avenues,” Steffan Dalsgaard, CEO of Golden Triangle, stated in a news release announcing the acquisition. “We are working directly with [Napa Wine Brands CEO] Arron [Johnson] and his team to grow their bulk inventory and launch all of these products for the world to enjoy.”
  • On May 20, 2021, Golden Triangle announced its entry into a letter of intent to acquire Sonder Fulfillment LLC, a leader in the industrial hemp and CBD space that is dedicated to driving forward the most powerful and efficacious cannabinoid products in the world. “Over the past two years, our operating partners have compiled a team of the best minds in the industrial hemp industry to create a totally vertical operation from seed to shelf,” Joshua Weaver, CEO of Sonder Fulfillment, stated in a news release announcing the LOI. “This acquisition by Golden Triangle Ventures will fully capitalize our operations and allow us to further expand our product lines and enter into new markets across the globe.”
  • On May 19, 2021, Golden Triangle announced the execution of a formal agreement with Robert “Bo” DuBose to purchase the remaining 49% of HyFrontier Technologies Inc., giving Golden Triangle 100% ownership of the technology company. “This acquisition has been something that Bo and I have been working towards for quite some time and we are both incredibly happy to have this executed,” Dalsgaard stated in a news release announcing the acquisition. “We knew that completing this agreement would show the world that we are both fully committed to our shareholders and the brilliant future of this revolutionary company.”
  • On May 12, 2021, Golden Triangle announced its acquisition of a top tier, professional sound system and formed a partnership with SuperKollider Sound LLC to provide a strategic benefit to the company’s entertainment division under Lavish Entertainment Inc. “We are very excited to acquire this unbelievable sound system,” Dalsgaard stated in a news release announcing the acquisition. “Hennessey Sound Design has always been one of my favorite systems on the market, and the team at SuperKollider Sound are true professionals in this space.”

Management Team

Steffan Dalsgaard is the Founder & Executive Chairman of Golden Triangle. He has a background in business development, with over a decade of experience representing and consulting with dozens of private and public companies. Mr. Dalsgaard consults with companies on all of their corporate objectives while providing a professional and corporate face to their organizations. He has built a strong reputation in the public relations industry and has a mission to work with emerging growth companies that are positioned to become significant businesses in their respective fields.

Robert DuBose is the company’s Chief Innovations Officer & Director and the CEO of HyFrontier Technologies Inc. Mr. DuBose is responsible for the success of the HyGrO product in the agricultural market. His experience in the design and production of hydrogen equipment goes back more than a decade, including PEMFC technologies since 2009 with his company, Aquafuel Inc. Mr. DuBose was raised in the farming and machine shop business, where he learned firsthand how much work and love goes into a successful crop, as well as how elements, which are out of the farmers control, can have adverse effects on finances. His belief that being able to deliver a solution to increase growth, yield, health, stamina of crops and profitability for farmers would be a win-win for all led him to create the HyGrO product.

Stuart Seim is the Chief Development Officer & Director of Golden Triangle. He began his career as an associate professor at the University of Manitoba in the field of outdoor and environmental education after receiving his master’s degree and completing advanced educational studies. Coming from a family with an extensive financial background, Mr. Seim became a stockbroker for major regional financial firm Robert W. Baird. In a short time, he became the Branch Manager for Baird in Minneapolis, Minnesota, while also serving as a Managing Director for Baird. During this time, Mr. Seim also served on the board of an industrial hearing company, which he helped to launch as a new company (The TK Group). Mr. Seim currently resides in Colorado, where he is an advisor to several organizations.

Golden Triangle Ventures Inc. (GTVH), closed Monday’s trading session at $0.09395, off by 21.7083%, on 1,047,495 volume. The average volume for the last 3 months is 434,238 and the stock's 52-week low/high is $0.018999999/$0.949899971.

Recent News

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF)

The QualityStocks Daily Newsletter would like to spotlight Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF).

Nextech (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29), an emerging leader in augmented reality (“AR”) for eCommerce, AR learning applications, AR-enhanced video conferencing and virtual events, today announced plans to launch its NFT hologram creator platform. The new offering will leverage the company's human hologram creator platform HoloX. Upon expected launch in the third quarter, customers will have the ability to seamlessly experience digital collectibles in augmented reality. To view the full press release, visit https://ibn.fm/kuryC

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF), based in Vancouver, Canada, is a leading provider of web-based augmented reality for e-commerce, advertising and virtual events, with technology ranging from simple 3D images to using 360-degree videos. Nextech AR provides businesses with a powerful end-to-end augmented reality platform designed specifically to increase online sales.

The company is currently pursuing four unique verticals with its innovative technology, including:

  • Virtual Conference Platform: Nextech’s advanced Augmented Reality and Video Learning Experience Platform for Events leverages an SaaS model to give organizations the ability to create engaging virtual event management and learning experiences. Automated closed captions and translations for over 64 languages are available. The global virtual events market was valued at $90 billion in 2020 by Grandview Research, and it’s expected to reach more than $400 billion by 2027.
  • ARitize™ for eCommerce: Launched in early 2019, the company’s SaaS platform for webAR in eCommerce serves as a ‘full funnel’ end-to-end e-commerce solution for the AR industry. The solution includes the Aritize360 app for 3D product capture, ‘Try it On’ technology for online apparel, 3D and 360-degree product views, ‘one click buy’ and much more.
  • ARitize™ 3D/AR Advertising Platform: Launched in Q1 2020, this ad platform is being marketed as the industry’s first end-to-end solution leveraging 3D asset creation for 3D/AR ads. In 2019, according to IDC, global advertising spend totaled roughly $725 billion.
  • ARitize™ Hollywood Studios: The studio is in development as a means of producing immersive content using 360-degree videos and augmented reality as primary display platforms.

Unique Marketing Strategy

Nextech AR’s efforts to disrupt the market for web-based augmented reality for e-commerce are supported by a unique go to market strategy. First, the company seeks to build or acquire platforms targeting a number of rapid growth industries, most notably AR, edTech, e-commerce, 3D/AR advertising and virtual & hybrid events.

After identifying these market opportunities, the company seeks to integrate new AR technologies into existing or novel platforms in an effort to secure market share and promote growth. These technologies include WebAR, Human Holograms, 360 Portals, ScreenAR, Genie in the bottle and AiRShow.

Nextech AR then aims to leverage these platforms to land and expand partnerships with a number of blue chip customers. The company’s current customer base includes the likes of Amazon, Johnson & Johnson, ViacomCBS, Toyota and Carnegie Mellon University.

Growth Capital

Nextech AR generates revenue through a software-as-a-service model from technology services, delivery of service revenue and sales of products through e-commerce.

As noted in its latest investor presentation, the company achieved record bookings in Q4 2020 of $7.3 million (estimated), marking a greater than 275% year-over-year increase. The company also realized greater than 235% revenue growth for calendar 2020, reporting $20 million for the 12-month period. Nextech AR attributes its 2020 increase in revenues to the contracts secured with new customers, expanded agreements with existing customers and additional conversions from e-commerce channels.

With its newly launched 3D ad network now bolstering its operations, Nextech AR is projecting revenues in excess of $50 million for 2021.

Recent Company Highlights

  • February 16, 2021: The company announced it has hired Zak Mcleod, formerly of Fastly, as its new Senior Director of Sales – EMEA. The company also announced that Rory Ganness, formerly of Salesforce.com, has joined the Nextech team as Director of Enterprise Sales – North America.
  • February 11, 2021: The company announced the launch of version 2.0 of its AiR Show app, an application that turns top music artists into interactive ‘live’ holograms, providing an immersive and engaging AR experience.
  • February 8, 2021: The company announced the launch of new standardized chat features within its Virtual Experience Platform (VXP) and recently-launched ARoom collaborative streaming solution. Nextech will also offer the chat platform as a stand-alone SaaS service externally, increasing the company’s revenue potential for 2021.
  • January 26, 2021: The company announced, in partnership with ARB Meetings and Events, it has signed a six-figure annual contract to supply its InfernoAR video conferencing and virtual events platform to NAMD.
  • January 25, 2021: The company announced that Strategic Site Selection (SSS), a 15 year old site selection leader in the meeting and events industry, has selected Nextech AR as a preferred channel partner, making Nextech’s industry leading virtual experience platform and services available to SSS clients.
  • January 20, 2021: The company announced that Microsoft’s Azure Cloud Services platform will be a standard offering across its virtual experience platforms and consumer apps, enabling hyper-scalable, secure and immersive events and applications for users.
  • January 15, 2021: The company signed a renewal agreement with Poly with an initial value of $470,000 for a six-month term and the potential for additional revenue after the six months.

Management Team

Evan Gappelberg is CEO and Founder of Nextech AR. He is an experienced operating executive specializing in creating, funding and running hyper-growth startups in both the public and private sectors. Notably, he took Take-Two Interactive Software Inc. (NASDAQ: TTWO) public with a market cap of $30 million and played a key role in guiding its growth to a current market cap of roughly $14 billion. Mr. Gappelberg has extensive experience as both a hands-on operating executive and a public markets professional.

Paul Duffy is the company’s President. He is a serial entrepreneur with over 25 years of experience in successfully starting, expanding, diversifying and selling global technology companies. Mr. Duffy is the creator of the HumaGram and inventor of the patent for Holographic Telepresence over the Internet (TOIP).

Augen Winschel is the COO of Nextech AR. He is an 18-year SAP executive with over 20 years of leadership experience in the areas of business management, business operations, marketing, product management, digital business and enterprise artificial intelligence.

Kashif Malik, CPA, CA, is the company’s CFO. He has over 15 years of financial experience spanning IPOs, M&A activity, corporate restructuring and capital raising. Mr. Malik has worked globally with public and private companies, including Merck & Company Inc. (NYSE: MRK), Real Matters Inc. (TSX: REAL) and Constellation Software Inc. (TSX: CSU). He obtained his Chartered Accountant designation while working at Deloitte.

Hareesh Acchi is the company’s President of 3D/AR Advertising. He is a 20-year Microsoft technology veteran with experience leading digital transformation and scaling businesses and enterprise organizations across the advertising industry.

Nextech AR Solutions Corp. (NEXCF), closed Monday’s trading session at $1.62, up 3.8528%, on 142,215 volume. The average volume for the last 3 months is 178,738 and the stock's 52-week low/high is $1.50/$5.41120004.

Recent News

HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF)

The QualityStocks Daily Newsletter would like to spotlight HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF).

  • HempFusion’s acquisition of Sagely Naturals opens the company to over 14,000 additional retail stores
  • It marks a massive milestone following the $17 million TSX IPO in January 2020
  • HempFusion looks to more than triple its 2020 revenue as this is part of the company’s expansion plan for 2021 and beyond 
  • The move builds on HempFusion’s five-channel strategy while playing into Sagely Naturals’ opportunities and strengths

2021 is proving to be a good year for HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO). In January, it completed its $17 million IPO to start trading on the Toronto Stock Exchange (“TSX”) (https://cnw.fm/I02G7). Fast forward to July; the company acquired Sagely Naturals in its most significant move yet as it works on a five-channel expansion strategy to conquer various markets, including the Middle East, China, India, Mexico, Europe, and South Korea (https://cnw.fm/Cy1BJ).

HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF) is a leader in the health and wellness CBD industry, providing innovative and diversified proprietary formulations utilizing the power of whole-food hemp nutrition.

Invested heavily in regulatory compliance, HempFusion aims to consistently meet and even exceed the high standards required by retailers and consumers – putting safety, quality and consistency first. In support of these efforts, the company is U.S. Hemp Authority Certified and is a current board member of the U.S. Hemp Roundtable, a coalition of leading companies committed to advancing safe hemp and CBD products.

HempFusion reported 1,750 shareholders and $18.3 million in cash as of June 30, 2020 – the second-largest cash position in its sector – with no debt. Looking ahead, the company is currently preparing to launch an IPO directly onto the Toronto Stock Exchange (“TSX”) senior board, where it has already reserved ticker symbol ‘CBD.U’. Learn More About HempFusion Upcoming IPO.

HempFusion is headquartered in Denver, Colorado.

HempFusion’s Proprietary Wellness Portfolio

The diverse product portfolio showcased by HempFusion includes 46 products that are currently on shelves. The company’s leading offerings include HempFusion-owned Biome Labs, HF Labs and Probulin. Due to the time and resources allocated to increasing the compliance of these proprietary products, HempFusion may have a competitive advantage and create additional retail opportunities that are not available for other CBD companies.

HempFusion’s Diversified Revenue Pipeline

HempFusion’s focus and investment into regulatory compliance has opened doors to major food and drug mass or big box retailers that are not available to other CBD companies. This strategic approach includes five distinct channels:

  • Natural Health Retailers
  • eCommerce
  • Big Box / Food and Drug Mass
  • Doctor Practitioner
  • Convenience

HempFusion’s Line of Products

HempFusion’s branded line of products is based on the company’s proprietary Whole Food Panoramic Full-Spectrum Hemp Complex. Each product is condition-specific, targeting needs such as sleep, energy and stress.

All of HempFusion’s products are made from DNA-verified, European Union registered, non-GMO, organic industrial hemp. The company’s offerings span multiple product categories, including:

  • Tinctures and capsules – These offerings make up the most popular product category in the $4 billion U.S. CBD market.
  • OTC topicals – HempFusion is one of the few CBD companies marketing FDA Drug Listed Topicals. The FDA compliance standards ensure that these products meet the standards set by larger national retailers.
  • Condition-specific OTC products – HempFusion has OTC products that are condition-specifically targeted, including:
    • OTC Pain Products – The global pain relief market for topicals is projected to reach $13.3 billion by 2025, with a CAGR from 2018 to 2025 of 7.4%.
    • OTC Eczema Products – The global dermatitis market is projected to reach $13.6 billion by 2026.
    • OTC Acne and Aging/Beauty Products – The global market for beauty and anti-aging products is currently estimated at $1.08 trillion.
    • OTC First Aid and Wound Healing Products – In 2019, the 10 top-selling first aid ointments in the United States generated over $650 million in sales.

Probulin Probiotics and Digestive Enzymes

Probulin Probiotics is a 100% wholly owned subsidiary of HempFusion Wellness Inc. and is currently one of the fastest growing probiotics brands in the United States, according to Spins syndicated data.

The Probulin product line addresses a wide range of consumer needs, including daily care, total care, women’s health and children’s products. The probiotics market represents a growing opportunity, as it is estimated to reach $7 billion globally by 2022.

Because of the diverse offerings of the Probulin line, it serves as HempFusion’s gateway to retailers who may not currently carry CBD products.

This ‘Trojan Horse Strategy’ is intended to allow the company to establish, develop and build relationships among these retailers. By achieving approved vendor status, the company may be able to facilitate faster onboarding times, enabling accelerated access to its CBD products in the future.

HF Labs and Biome Research – Doctor and Practitioner Product Lines

The HF Labs and Biome Research product lines are directed toward doctors and practitioners and cater to hospitals, compounding pharmacies and free-standing dispensaries. With an estimated target market of 28,000+ integrative medical doctors and 70,000+ licensed chiropractors in the United States, these offerings create a unique market opportunity as HempFusion continues to broaden its footprint in the CBD industry.

Research on CBD and Human Safety

HempFusion is one of 12 CBD companies selected to participate in ValidCare’s groundbreaking study regarding CBD and human safety, which is expected to be complete by the end of October 2020. The study is designed to address previous questions from the FDA regarding CBD products.

As part of this study, HempFusion and the other selected companies will be conducting human trials to determine if the daily use of full-spectrum hemp-derived CBD or CBD isolate impacts the human liver.

Management Team

Jason Mitchell, N.D., is the co-founder, Director and CEO of HempFusion. He has over 20 years of experience in the natural products industry and is a naturopathic doctor certified by the ANMCB. Mitchell received his doctorate from the Trinity College of Natural Health and is a member of the American Naturopathic Medical Association and the CNHP. He is an expert in supplemental formations and was responsible for successfully creating and launching over 300 industry-leading products during his 15-year tenure at Country Life Vitamins.

Ian DeQueiroz is the Chief of Brand Strategy & Partnerships and a Director for HempFusion. He is a serial entrepreneur with experience in early-stage cannabis and hemp companies. In 2010, he acquired his first cannabis CO2 extraction company in the United States. DeQueiroz has facilitated the licensing process for many companies in the United States, as well as one of Jamaica’s premier cannabis companies, Epican Medicinals Ltd.

Jon Visser is HempFusion’s Chief Revenue Officer. He has over 25 years of experience in all areas of sales and marketing, with a proven track record of consistently driving growth across all major channels. Visser was previously the Senior Vice President of Sales at Navajo Inc., a multi-national manufacturer/distributor of brands like Pennzoil Automotive Supplies, Piranha Eyewear and Navajo Inc., the largest distributor of trial- and travel-sized health and beauty products in the United States. Visser grew annual sales from $60 million to $128 million in less than three years while at Navajo Inc.

Bruce Valentine Jr. is the Chief Financial Officer of HempFusion. He has a proven track record working with high-growth companies and was named CFO of the Year in 2013 by the Northern Colorado Business Report. Valentine is the former CFO of Otter Products and has over 15 years of financial management experience.

Ola Lessard is the Chief Marketing Officer of HempFusion and is also the President of the U.S. Hemp Roundtable. She has experience in marketing creative and effective brand strategies. She is a former Vice President of Marketing at Barlean’s, an award-winning supplements provider based in Washington.

Nancy Angelini is the Director of the Doctor/Practitioner Channel. She has over 25 years as an active, licensed practitioner. Angelini travels the country as a lecturer and product manager. She is responsible for opening doors to some of the largest doctor/practitioner networks in the United States.

Daniel Brody is the Chief Corporate Officer of HempFusion. He is the co-founder and former Vice President of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF). Brody has been instrumental in listing multiple world-class cannabis companies, including TGOD, Emblem Corp. and Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF). Before joining the cannabis industry, he spent seven years working at two leading Canadian brokerage firms.

HempFusion Wellness Inc. (CBDHF), closed Monday’s trading session at $0.265, off by 5.3571%, on 42,721 volume. The average volume for the last 3 months is 144,661 and the stock's 52-week low/high is $0.25/$3.69000005.

Recent News

Grapefruit USA Inc. (OTCQB: GPFT)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit USA Inc. (OTCQB: GPFT).

Grapefruit USA (OTCQB: GPFT), a fully licensed premier manufacturer and distributor in the legal cannabis marketplace, is committed to being an industry leader by using science and technology to create truly disruptive products for both the recreational and medicinal cannabis marketplace. GPFT recently announced that it is accepting cryptocurrency as payment for its full-spectrum THC Hourglass time-release technology-powered products through its newly launched e-commerce platform, joining other leaders in the cannabis space in paving the way. A recent article reads, “Grapefruit is building a well-earned reputation for pioneering future-looking ideals and products. The company’s flagship product features cutting-edge science and technology that solves the age-old problem of THC and other cannabinoids not being easily absorbed through the skin. Grapefruit’s Hourglass topical cream uses patented micro-sized particles to slowly deliver THC and a wide range of cannabinoids through skin topical administration. No other topical cream product in the market provides users with the holistic benefits of the range of cannabinoids found in Hourglass, including THC+CBD, CBN, CBG, Delta8, THCV and CBE.” To view the full article, visit: https://cnw.fm/Z7C8D

Grapefruit USA Inc. (OTCQB: GPFT) is a Delaware corporation that is a fully licensed premier cannabis manufacturer and distributor in the legal cannabis marketplace with its own patented and branded line of products.

The company manufactures its patented product line and distributes it, along with other cannabis products, to all properly licensed cannabis product businesses.

Grapefruit is the only cannabis company that has harnessed cutting edge science and technology to bring patented, truly disruptive products to the medicinal and recreational cannabis marketplace, fundamentally changing the way individuals use THC, CBDs and hemp-derived CBDs and capitalizing on the rise in demand for these unique products.

Headquartered in Los Angeles, California, the company has held licensing in the state for manufacturing and distributing cannabis since 2018. Grapefruit currently owns and operates a California-licensed cannabis extraction laboratory and a licensed wholesale distribution facility in the Coachillin’ Canna-Business Park near Palm Springs, California. Grapefruit is managed by a team of experts who possess the experience, skills and resources required to succeed in the competitive cannabis marketplace.

Hourglass™ Topical Delivery Cream

Grapefruit’s patented Hourglass™ topical delivery cream has solved the previously insurmountable difficulties of efficient skin absorption of THC and other cannabinoids.

Hourglass™ allows users to experience a sustained and holistic delivery of THC/cannabinoids providing “the entourage effect” following initial application to the skin. Additional applications may be made confidently and discreetly at the user’s discretion. There simply is no other product on the planet which successfully utilizes a patented time release THC and CBD delivery mechanism to deliver the holistic benefits of cannabis to those who need it.*

Hourglass™ is a unique, highly concentrated full spectrum time-release topical delivery cream that releases a holistic amount of THC, along with a wide range of cannabinoids (or just CBD), over a four- to eight-hour period.* The formula then comes off through the natural sloughing process of dead skin cells. Hourglass provides many holistic benefits, all of which promote health and wellness as it’s number one goal.

Hourglass™ provides users with an entourage effect of THC plus a wide range of cannabinoids, including CBD, Cannabinol (CBN), Cannabigerol (CBG), Delta-8, Tetrahydrocannabivarin (THCV), and Cannabielsoin (CBE) in a Patchless Patch™ system that is novel and proprietary to the company.

Hourglass™ Topical Delivery Cream has fundamentally changed the way individuals use THC and cannabinoids to obtain their holistic benefits.* As a result, smoking cannabis or hemp flowers and orally consuming edibles, which are metabolized in the gut and liver resulting in uneven reactions, are no longer the exclusive ways to receive both the medicinal and recreational benefits of THC/cannabinoids.* Now for the first time in history, there is an effective, easy to use third choice – Hourglass™ by Grapefruit.

*This product is not regulated by the FDA and is not intended to cure, mitigate, treat or prevent disease.

Grapefruit Cannabis Services

Grapefruit distributes cannabis flower and cannabis products, including its own proprietary products, as well as a wide range of services, to other properly licensed cannabis product businesses. These products and services include:

  • Distribution – As a premier licensed distributor, Grapefruit handles the distribution of all-things cannabis throughout California, specializing in bulk AAA exotic indoor flowers sourced from farms located in the state. The wholesale distribution arm facilitates flowers, fresh and dry frozen, and oil transactions in bulk wholesale form. Its wholesale distribution arm distributes its patented Hourglass™ topical delivery cream.
  • Manufacturing – The company owns and operates a fully licensed and compliant ethanol extraction lab that produces a high-quality distillate. This THC Honey Oil distillate is a universal product used in everything, including infused edibles, tinctures, creams and even vape cartridges. Its patented Hourglass™ cream is also manufactured exclusively at Grapefruit’s Coachillin lab facility by highly trained Grapefruit personnel.
  • Hourglass™ Topical THC+CBD Delivery Cream – The company’s patented Hourglass™ Topical Delivery Cream has solved the inherent difficulties of efficient skin absorption of THC and cannabinoids such as CBD, CBN, CBG and CBC, as well as hemp-derived CBDs and cannabinoids. Hourglass™ is a truly novel and disruptive delivery technology which fundamentally changes the way individuals will use THC and CBD to obtain their holistic benefits.*
  • Rainbow Dreams – Rainbow Dreams is the company’s lifestyle brand designed for the recreational cannabis marketplace. The brand captures the party-mode of the 1970s and offers vape carts with unique cannabis strains and natural flavors. The product fulfills an important marketplace niche – a top-shelf product that is competitively priced.

Market Outlook

The global cannabis market was valued at $10.6 billion in 2018. During the forecast period from 2019 to 2026, the market is expected to grow at a CAGR of 32.92%, reaching a projected value of $97.35 billion by the end of 2026 (https://nnw.fm/eTMSX).

Cannabis legalization has been gaining momentum around the world. Grapefruit is currently in a position to disrupt the industry – both the medicinal and recreational sectors – with proprietary products and manufacturing processes that harness the power of cutting-edge science and technology.

Management Team

Bradley J. Yourist is the Chief Executive Officer of Grapefruit. Mr. Yourist has been a follower of the medical cannabis market since the late 1990s, which allows him to understand the distribution model and the legal issues facing the market. He has also seen the benefit of cannabinoids in the medical industry. He understands the planning and operations of Grapefruit’s cannabis distribution arm and extraction lab and was instrumental in the planning for the facility.

Daniel J. Yourist is the Chief Operating Officer of Grapefruit. He is a licensed attorney in the state of California and a Real Estate Broker. Mr. Yourist is a licensing expert in the cannabis space and has gained extensive experience in all areas of managing a cannabis business in California. He ensures that every aspect of the company is run in accordance with state and local cannabis laws and regulations.

Grapefruit USA Inc. (OTCQB: GPFT), closed Monday’s trading session at $0.039, off by 2.378%, on 258,501 volume. The average volume for the last 3 months is 844,580 and the stock's 52-week low/high is $0.019999999/$0.310000002.

Recent News

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

The QualityStocks Daily Newsletter would like to spotlight XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT).

  • Researchers theorize that psychedelic substances differ from other recreational drugs because they do not lead to compulsive use or addiction and neither do they harm an individual’s brain. An analysis conducted by researchers from the Department of Neuroscience at the Norwegian University of Science and Technology proves this, having found that the use of peyote, psilocybin mushrooms or LSD does not increase an individual’s risk of developing mental health conditions. This long history of psychedelic use by various communities means that companies such as XPhyto Therapeutic Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) may not have a lot of work to do to prove the safety profile of medicines made from psychedelics, including psilocybin and MDMA.
  • Research has found that medical marijuana possesses therapeutic benefits, and with more states across the country legalizing the use of medical marijuana in alleviating and managing symptoms of various indications, it is important to acquaint yourself with what this means for you, especially if you qualify to use medical cannabis. Some companies, such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), have taken the added step to develop cannabis-based treatments that they hope will be approved by regulators, such as the FDA, for use by patients even in regions where medical marijuana isn’t legal yet.

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. This includes products that are being readied for commercialization within the coming weeks, such as a rapid COVID-19 PCR test kit that reduces turnaround times to less than 30 minutes.

The company has research and development operations in North America and Europe and an operational focus in Germany. Its regulatory approval and commercialization focus is currently on products for the European market.

XPhyto was founded in 2017 and is headquartered in Vancouver, British Columbia.

Business Strategy & Milestones for 2021

On January 18, 2021, XPhyto issued a news release detailing its business strategy for the coming year. The company noted that it is “on the cusp of transformational change as product development programs advance from the laboratory to the clinic.” In addition to continuing to leverage its scientific expertise and operations in North America and Europe for product development and optimization, XPhyto intends to pursue growth through the commercialization of existing products and adherence to a focused investment strategy targeting impact-driven innovation with “the potential for extreme value creation.”

In particular, XPhyto is well positioned to execute on opportunities across its current business divisions, including:

  • Commercialization of infectious disease diagnostics
  • Clinical validation of transdermal and sublingual drug formulations
  • Continued investment and development in psychedelic medicine

“2020 was a very productive year for XPhyto. We made significant progress in all areas of our business,” Hugh Rogers, CEO & Director of XPhyto, stated in the update. “We have ambitious milestones for 2021 with multiple product launches on the horizon, multiple clinical drug programs underway, and an aggressive commitment to psychedelic medicine. I am extremely confident that our team can execute on the company’s business plan for 2021.”

Infectious Disease Diagnostics

XPhyto’s lead diagnostic product, secured through an exclusive global commercialization agreement with 3a-diagnostics GmbH (“3a”), is a rapid and highly portable PCR diagnostic test. Notably, PCR testing “has emerged as the only internationally recognized standard for COVID-19 testing” and is expected to play a key role in facilitating the recovery of the domestic and international travel industries, among others.

Successful validation of the PCR system was achieved in Q4 2020, and XPhyto has expressed confidence that it will achieve European commercial (CE-IVD) approval in Q1 2021. In preparation for this milestone and an anticipated Q1 product launch, the company is currently in discussion with manufacturing and distribution partners in Europe and the Middle East.

In addition to COVID-19 products, XPhyto and partner 3a are developing and commercializing a portfolio of low-cost oral biosensors. The company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis for which XPhyto is targeting a late 2021 European commercial approval.

XPhyto does not make any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Drug Formulation & Delivery

In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), reported significant advancement in four therapeutic programs targeting neurological indications with significant market demand. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.

XPhyto will look to build on this progress in 2021, with plans to complete human pilot studies evaluating its four lead therapeutic products:

  • Rotigotine transdermal patch for Parkinson’s disease
  • CBD oral/sublingual strip for treatment resistant epilepsy
  • THC oral/sublingual strip for anorexia/nausea
  • CBD:THC (1:1) oral/sublingual strip for multiple sclerosis associated spasticity

Per its 2021 business update, the company is currently in “ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.”

Psychedelic Medicine

Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) demonstrating strong potential for a variety of mental health conditions. XPhyto is positioned to capitalize on this promise through two strategic initiatives:

  • An agreement for the development of industrial scale biotechnology processes for the production of psilocybin
  • An agreement for R&D related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA and DMT, among others

XPhyto intends to advance and expand its programs focused on the industrial scale production of psychedelic API in 2021. The company also plans to launch new programs for the development of psychedelic drug formulations, with a focus on sublingual and transdermal therapeutics and the integration of these products into established clinical programs relating to mental health indications.

Management Team

Hugh Rogers is the CEO and Director of XPhyto Therapeutics Corp. He is an entrepreneur and lawyer with private and public start-up company experience in various industries and operational roles. His recent advisory work has focused on public listings and corporate restructuring. This restructuring has occurred in the life science (cell therapy and medical device) and natural resources (natural gas co-gen and conventional oil) industries. Mr. Rogers holds a bachelor’s degree in Cellular Biology and Genetics and a law degree. He is a member in good standing of the Law Society of British Colombia.

Christopher Ross is the CFO of XPhyto. He is a professional accountant with broad financial experience across numerous industries, including forestry, distribution, construction, mining and multi-family real estate. He has provided advisory services to private and public companies in the areas of financial accounting, strategic analysis, audit and taxation. Mr. Ross holds a bachelor’s degree in commerce. He is a member in good standing with the Chartered Professional Accountants Association of British Columbia.

Wolfgang Probst serves as Director of XPhyto and Managing Director of BUNKER Pflanzenextrakte GmbH. He is a seasoned management and financial consultant based in Bavaria, Germany. He has consulting experience as branch head working with private clients and corporations of high net worth. In 2017, Mr. Probst assumed the CFO role of BUNKER and continues to play a key role in its operational and financial development.

Professor Dr. Raimar Löbenberg serves as Director of XPhyto. He holds a Bachelor of Science in pharmacy from Johannes Gutenberg-University and a Ph.D. in pharmaceutics from the Johann Wolfgang Goethe-University. He is the co-founder of RS Therapeutics Inc., which concentrates on foam-based topical drug delivery systems.

Professor Dr. Thomas Beckert is the Founder and Managing Director of Vektor Pharma TF GmbH. His expertise includes the formulation and machine development of transdermal therapeutic systems and ODFs. Professor Beckert holds a Bachelor of Science in pharmacy from the University of Freiburg and a Ph.D. in pharmacy and economics from the University of Tubingen.

XPhyto Therapeutics Corp. (OTCQB: XPHYF), closed Monday’s trading session at $1.32, off by 1.3084%, on 19,630 volume. The average volume for the last 3 months is 39,207 and the stock's 52-week low/high is $1.00/$3.0999999.

Recent News

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF)

The QualityStocks Daily Newsletter would like to spotlight PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF).

  • While all wines are plant-based, not all of them are vegan because traditional winemaking employs animal-based fining agents
  • Vegan wines are clarified and stabilized using either bentonite or natural settlement, but vegans struggle to find such wines
  • PlantX recently added vegan wines to its expanding product selection on its US e-commerce platform, targeting the growing population of vegans in the US
  • The move also appears to be leveraging the trends in both the alcoholic beverage market and the e-commerce sector

While all wines are derived from grapes and sometimes yeast – meaning they are plant-based – not all wines are vegan. This is because some aspects of traditional winemaking, particularly the fining process, employ animal products. A process that stabilizes and clarifies the wine by removing hydrogen sulfide, bitter flavors (or rough tannins, to wine fiends), and microscopic particles that may cause the wine to become cloudy or hazy after bottling, fining typically uses egg whites, as well as fish and milk derivatives. This creates an end product that isn’t vegan – vegans do not consume any form of animal product. In contrast, vegan wines, which still undergo the fining process, do not use animal derivatives. Wineries instead rely on bentonite, a clay, or forego fining agents altogether – given ample time, the impurities settle naturally out of the wine. So, according to a 2018 Washington Post article, the use of animal-based fining agents may not be as widespread as many think (https://ibn.fm/PXiUx). However, because most of the wines available for sale are usually mass-produced and rushed to the market, one cannot be too sure. In fact, vegans have voiced their frustrations at not readily finding vegan wines in shops or restaurants (https://ibn.fm/EONQb). This is where PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), a company intent on redefining the plant-based community through e-commerce, comes in. PLTXF recently announced it is now offering vegan wines as part of its expanding product selection on its US e-commerce platform. The addition, announced July 12, will feature a curated selection of high-quality vegan wines from Gravel Bar Winery, Pino Cellars, Veuve Clicquot, and Rare Earth (https://ibn.fm/qWi5u).

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) aims to redefine the plant-based community through e-commerce, with a core objective of becoming the most trusted and convenient destination for people living plant-based lives. PlantX is a multifaceted marketplace providing consumers all things plant-based ranging from an efficient e-commerce experience, connecting consumers with interactive PlantX brick-and-mortar stores, and a PlantX home delivery system for products, meals, recipes and more.

PlantX is a high-growth technology company focusing on consumer-packaged goods (“CPG”) for the plant-based opportunity. The PlantX platform aims to serve as the digital face of this community with its one-stop-shop for everything plant-based, including:

  • An easy-to-use e-commerce shopping experience featuring the following:
    • Plant-based grocery items (from all your pantry needs to vitamins, cosmetics and even pet food)
    • Meal delivery with recipes created by well-known plant-based chefs throughout the world
    • Plant shop – delivering a wide variety of affordable indoor houseplants to homes across Canada and the U.S.
    • Easy to follow plant-based recipes every week
    • Partnerships with restaurants, nutritionists, chefs and brands
    • A community of like-minded individuals
  • State-of-the-art flagship PlantX locations

Since first launching in February 2020, PlantX Life has offered various services available through its comprehensive platform. This online marketplace features over 10,000 items across diverse product categories such as pantry items, beverages, personal care, pet food and indoor plants. In addition, PlantX has collaborated with renowned chefs and nutritionists to create 20 unique and pre-made meals delivered to the comfort of your own home.

Headquartered in Vancouver, Canada, PlantX’s mission is to spearhead the plant-based movement, celebrate and promote health and wellbeing, raise plant-based awareness in a hyper-palatable world, connect with global consumers and forge a welcoming plant-based community.

The company currently reports 4 million stock options and 24 million warrants outstanding, with a total of 88,832,159 shares issued and outstanding and a total market cap of $89.9 million on January 18, 2021. PlantX has continued to catalyze its capital markets dynamics by applying to list its common shares on the Nasdaq Capital Market (“NASDAQ”). The company’s common shares are eligible for electronic clearing and settlement through The Depository Trust Company (“DTC”) in the United States.

Market Outlook

With its comprehensive e-commerce platform, PlantX is strongly positioned for a prominent role in the fast-growing plant-based food market, e-commerce and the online food delivery sectors. The global plant-based food market is expected to reach $74.2 billion by 2027, expanding at a CAGR of 11.9%. Similarly, the online food delivery market has steadily grown, especially during the current pandemic. This trend seems here to stay. In the United States alone, the sector is expected to report $28.5 billion by 2024, with companies such as UberEats experiencing 152% increases in food deliveries in the summer of 2020.

Complementary to these trends, and as a result of the COVID-19 pandemic, online sales and digitization have also both grown exponentially in 2020. Grocery shopping has seen a remarkable transition to e-commerce, with online grocery sales growing by 53% in 2020. Amid the pandemic-imposed physical interactions and related consumer behavior change, large retailers have been compelled to meet this surge in e-commerce demand. For example, Whole Foods Markets has increased its online sales capacity by over 60% in 2020. The global meal kit delivery system is also becoming increasingly popular and is expected to achieve a market value of $19.92 billion by 2027, expanding at a CAGR of 12.8%.

PlantX aims to capitalize on this anticipated exponential market growth of the plant-based, e-commerce and home-delivery industries.

Digital Platform for the Plant-Based Community

The digital interface provided by PlantX spans a health and wellness initiative that offers thousands of plant-based products, meal delivery, indoor plants, recipes and a community space for those who are like-minded about plant-based products and healthy lifestyles. PlantX has been compared to Amazon, except with a focused tailored selection of plant-based offerings.

PlantX provides everything a consumer needs for plant-based living at the click of a button. With PlantX, customers can:

  • Shop
  • Find recipes
  • Read blogs
  • Join a community forum
  • Listen to podcasts
  • View cosmetics
  • Research vitamins
  • Purchase plant-based pet foods
  • Read corporate updates
  • Subscribe to an insightful newsletter

The company’s website was designed with a user-friendly interface that allows customers to visit the site and easily find what they need. Forums for communicating with a plant-based community make it easier to swap recipes or locate the best restaurants serving vegan and vegetarian-friendly cuisine.

PlantX Flagship Locations – British Columbia (Canada), San Diego (California), & the State of Israel

PlantX will link the e-commerce platform to flagship brick-and-mortar stores for a highly sensory customer experience. This is anticipated to drive corporate growth and global brand recognition.

These PlantX branded flagship locations will first launch in:

Customer engagement, education and creating a global plant-based community will be furthered through this initiative.

PlantX Restaurant Partnerships

With consumers becoming better informed and more health and environmentally conscious, a growing number of restaurants will start catering to the needs of customers who are vegan, vegetarian, have food-allergies (or specialized diets), or simply want to eat healthier.

PlantX proactively aims to support this change and help restaurants meet the needs of the plant-based community. Restaurants that want to increase revenue, drive traffic and make an impact can therefore partner with PlantX to better serve their customers by expanding and refining their menus.

Future Goals for PlantX Life

Having successfully completed all of the milestones that PlantX had set-out to achieve in the second half of 2020, PlantX strives to continue scaling through organic growth, strategic partnerships and accretive M&A opportunities. The upcoming plans from PlantX includes a global expansion strategy for distribution in North America, Europe and Israel.

Verticals launched in 2020 include:

  • New meals and programs by renowned chefs
  • Flagship PlantX locations
  • PlantX branded goods
  • United States meal delivery and LIV
  • Online peer-to-peer fitness

Management Team

Sean Dollinger, the Founder of PlantX Life Inc., has had a very active professional career that started when he was only 17. While still in college, he started a delivery service that soon became one of Canada’s largest delivery firms (before companies like Postmates and Uber Eats ever existed). In 2014, Mr. Dollinger founded Namaste Technologies, the largest international e-commerce distributor of vaporizers and accessories. He brought Namaste public and turned it into a $1.2 billion business in two years. After finding a plant-based diet himself, and seeing the massive benefits that it provided for him, he decided he wanted to find a way to give back to the community and focus on something he loves. PlantX Life was born from this desire and became his passion project. He truly walks the talk.

Julia Frank is the CEO of PlantX Life. She has an MBA in digital entrepreneurship, and, in her past roles, she set up renowned strategies for large corporations like BMW and Daimler in Germany. Beyond her professional business prowess, Ms. Frank finds tremendous joy in preparing delicious and nutritious plant-based meals and is the face of the company. She practices a healthy and active lifestyle that includes experiencing as many cultures as possible to add more knowledge of the industry at large. This globally inclusive perspective gives her the unique advantage of being able to see plant-based living from all angles.

Lorne Rapkin, CPA, CA, LPA, is the President and CFO of PlantX Life and is also a partner at Rapkin Wein LLP. He has experience with clients in almost every industry, including finance, professional services, real estate, automotive, media and manufacturing. Mr. Rapkin works very closely with investment and public firms, seeking to comply with IFRS accounting standards. His roles often require him to work with management on go-public transactions, acquisitions and mergers. His keen attention to detail is an asset to any client he works with, and PlantX is no exception.

Alex Hoffman is the company’s CMO and has spent the last 10 years in the creative field cultivating her passion for design and appreciation for beauty. This is apparent in all of the creative decisions and outcomes seen at PlantX. Her role within the company is to oversee all of the brand marketing activities, establish and execute key processes for rapid growth, and work closely with management to refine the brand’s message for key segments and emerging opportunities. She has a sharp vision for exactly what’s needed to convey the company’s core messages and principles to both the public and investors, and she is a visionary with respect to creative marketing ideas and concepts.

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), closed Monday’s trading session at $0.276, off by 1.4286%, on 88,416 volume. The average volume for the last 3 months is 175,566 and the stock's 52-week low/high is $0.262699991/$1.85000002.

Recent News

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)

The QualityStocks Daily Newsletter would like to spotlight Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF).

new study conducted by researchers from the Memorial Sloan Kettering Cancer Center has discovered that after undergoing bladder removal operations, the risk of high-grade bladder cancer recurrence decreased after the nivolumab formulation was administered to patients. Together with a group of researchers, Dr. Dean Bajorin, who is a medical oncologist at the institute, evaluated more than 700 patients who had a high risk of urothelial cancer recurring after their kidney, ureter or bladder had been removed because of advanced metastatic bladder cancer. Patients can look forward to remedies that offer even better clinical outcomes given that a lot of companies, including Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), are doing intensive research and development to make the treatment of bladder cancer more effective.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.

The company’s first product is the i/Blue Imaging™ System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells.

Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources.

i/Blue Imaging™ System

The conventional method used for visualizing bladder cancer during surgery is an endoscopic procedure called a cystoscopy. This procedure uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Blue light cystoscopy uses blue-filtered white light, which addresses the limitations of white light (such as detecting flat tumors and the fine edges that may result in cancerous cells being left behind during removal).

Blue light uses a contrast agent that causes cancer cells to fluoresce when illuminated. Surgeons are then able to more effectively visualize and resect the margins of bladder tumors to reduce the risk of recurrence. Notably, the use of the white light is still necessary during a blue-light procedure so that the surgeon can orient their position within the bladder.

Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images.

The i/Blue Imaging System is unlike other methods available on the market today. It is external to the body and can attach to almost any endoscope model currently in use. This way, hospitals adopting Imagin Medical’s technology have the ability to use their current endoscopes without the need to purchase new equipment.

Bladder Cancer Prevalence

The company’s initial focus is bladder cancer, which is the sixth most prevalent form of cancer in the United States. In 2020, the number of new bladder cancer cases is expected to total 81,400, accounting for 4.5 percent of all new cancers diagnosed. The death rate in 2020 for cancer deaths associated with the bladder is forecast at 17,980, or 3% of all cancer-related deaths (https://ibn.fm/qLi3l).

Bladder cancer also has one of the highest recurrence rates among all forms of cancer, leaving about 600,000 people in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing this issue, and i/Blue demonstrations have indicated that the use of both white and blue light can enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates.

Based on Verified Market Research, the global bladder cancer research market was valued at $3.43 billion in 2018. It is estimated to grow with a CAGR of 4.03% through 2026, resulting in a projected $4.71 billion market (https://ibn.fm/rI7G6).

Management Team

E. James Hutchens is the Chief Executive Officer of Imagin Medical Inc. He is a proven entrepreneur with over 30 years of experience in management in the medical technology industry. Hutchens served as a managing partner with Origin Partners, a $55 million early-stage venture capital fund. He was also the founder and CEO of both Microsurge Inc. (a venture-backed minimally invasive surgical company) and Choice Therapeutics (an advanced wound-care company). He is a former member of the Board of Directors of the Brigham and Women’s and Faulkner hospitals. Hutchins holds a BS in Business Administration from Boston University.

John Vacha is the company’s Chief Financial Officer. He has 20 years of experience in the health care industry. Prior to Medtronic’s acquisition of Intact Medical Corp. in 2017, Vacha was the company’s President, CEO and a board member for seven years. He is a licensed CPA in Massachusetts. Vacha has an MBA and an MS in Accounting from Northeastern University in Boston. He is also a serving member of the Board of Directors at the South Boston Health Center. He currently has two patents in electrosurgical instrumentation.

Michael G. Vergano is the Director of Operations of Imagin Medical. He has been the President of The Harvest Group Inc. since 1998, where he has provided consultant services for startups and major corporations. Vergano has over 30 years of experience in the medical device industry. He has held management positions at Microsurge Inc., Ciba Corning Diagnostics and Boston Scientific Corp. He is currently the holder of 11 medical device patents and holds a BS in Mechanical Engineering from Tufts University.

Pam Papineau is the company’s Director of Regulatory Affairs. She has over 30 years of experience in quality and regulatory affairs with Boston Scientific, Baxter and Cogentix. She has served as a consultant on various devices including imaging, endoscopy, orthopedic, GI/GU and cardiovascular applications. Papineau has successfully prepared dozens of FDA pre-market and EU submissions to support CE marking of a broad spectrum of medical devices. She is an ASQ Certified Quality Engineer, a Certified Biomedical Auditor, a Certified Quality Auditor and an ISO 13485:2016 Lead Auditor, and she is certified by the Regulatory Affairs Professional Society – U.S., EU and Canada. Papineau works with the company’s legal counsel to prepare pre-submission meetings with the FDA and activities through the regulatory approval process.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), closed Monday’s trading session at $0.3888, up 1.8601%, on 14,501 volume. The average volume for the last 3 months is 6,032 and the stock's 52-week low/high is $0.200000002/$1.16999995.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Figures show that the global production of uranium will recover by more than 3% this year, owing to the resumption of operations at Canada’s Cigar Lake mine as well as other mines that were suspended last year. In addition, while the mineral’s production in Australia will continue to decrease because of the halt in operations at the Ranger mine, Russia and Kazakhstan will record significant increases in their output. A good example would be the United States, which is currently the biggest producer of nuclear energy globally, with Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) being the largest U.S. producer of this energy-dense mineral. The country is currently debating on whether it shouls extend the operating life of its plants to a hundred years.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Monday’s trading session at $5.34, up 4.501%, on 1,795,821 volume. The average volume for the last 3 months is 3.326M and the stock's 52-week low/high is $1.41999995/$7.82999992.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading